Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy
Paper cited by one bottleneck page and 22 idea pages, indexed on Europe PMC as PubMed record 29710129 and published in JAMA Oncology; the citing pages link this DOI, which is how the record was matched.
Overview
Europe PMC indexes no abstract for this record; the title is the only text available.
Indexed on Europe PMC as PubMed record 29710129 (DOI 10.1001/jamaoncol.2018.0977). Matched by DOI alone: one bottleneck page and 22 idea pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
One bottleneck page and 22 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.
Similar pages
not linked directly; found by shared links- CompanyInterius BioTherapeutics
Shares In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, Manufacturing cost and time for living and radioactive medicines.
- CompanyUmoja Biopharma
Shares In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, Manufacturing cost and time for living and radioactive medicines.
- TermAlpha vs beta emitters
Shares Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211, Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit, Manufacturing cost and time for living and radioactive medicines.
- CompanyOrna Therapeutics (Eli Lilly)
Shares In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, Manufacturing cost and time for living and radioactive medicines.
- Key paperEfficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
- Key paperThe long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
- Key paperSAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.
- TrialStudy of Out of Specification for Tisagenlecleucel
Shares Non-viral CAR-T (transposon or CRISPR knock-in) as the default manufacturing route, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma.